Medigene AG’s Post

Today Marengo Therapeutics announced a clinical study collaboration with Gilead Sciences to evaluate Marengo’s Invikafusp alfa (STAR0602) and Gilead’s Trodelvy® in both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers.    The collaboration will evaluate the combination of Marengo’s first-in-class TCR Vb selective dual T cell agonist, STAR0602 (Invikafusp alfa), with Trodelvy (sacituzumab govitecan-hziy) Gilead’s Trop-2 directed ADC in a new multi-center Phase I/II clinical study (START-002). This innovative combination approach will leverage two unique modalities to target and potentially eradicate cancer cells. Read our press release to learn more: https://lnkd.in/e6kX7Nhb

INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors In the absence of selective CDK2 inhibitors, precise impact of pharmacologic inhibition of CDK2 is not known, INX-315 is all set to fill that gap as a novel and potent CDK2 inhibitor with high selectivity over other CDK family members Using cell-based assays, patient-derived xenografts (PDX), and transgenic mouse models, INX-315 (i) promotes retinoblastoma protein hypophosphorylation and therapy-induced senescence (TIS) in CCNE1-amplified tumors, leading to durable control of tumor growth; (ii) overcomes breast cancer resistance to CDK4/6i, restoring cell cycle control while reinstating the chromatin architecture of CDK4/6i-induced TIS; (iii) delays the onset of CDK4/6i resistance in breast cancer by driving deeper suppression of E2F targets. https://lnkd.in/g7sWGEmT https://lnkd.in/g-4djMEt

Partnership to Develop Next-Gen Radioligand Medicine for Rare Cancers!! 🤝 🎯 !! Collaboration between Sanofi, Radiomedix, Inc. and Orano Med focuses specifically on the late-stage project, AlphaMedix (212Pb-DOTAMTATE), which currently is being evaluated for the treatment of adult patients with unresectable or metastatic, progressive somatostatin-receptor expressing neuroendocrine tumors (NETs), a rare cancer. AlphaMedixT is a targeted alpha therapy (TAT) which consists of a somatostatin receptor-targeting peptide complex radiolabeled with lead-212 (212Pb) that serves as an in vivo generator of alpha particles. #AlphaMedix has recently been granted Breakthrough Therapy Designation in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) from the US FDA for patients who are naïve to peptide-receptor radionuclide therapy. #sanofi #radiomedix #oranomed #competitiveintelligence #pharma #cancer

At this year’s CHI Summit, Kirsty Crame - van Nierop presented a comprehensive overview of the Company's lead candidate MDG1015 highlighting its technologies to enhance T cell receptor engineered T cell (TCR-T) therapies. MDG1015, a first-in-class, third generation TCR-T therapy, is derived from Medigenes End-to-End Platform and #IND-ready. It targets the tumor-specific cancer testis antigen NY-ESO-1/LAGE-1a and is armored and enhanced with the proprietary PD1-41BB costimulatory switch protein. Subject to financing, a first-in-human trial for MDG1015 is planned for gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma with IND/CTA filing targeted for 2H 2024. Read here the full PR: https://lnkd.in/dZvU7kyN Find more details on Medigene AG End-to-End Platform here: https://lnkd.in/eDjmquVJ

Molecules of the Month – July 2024 | https://lnkd.in/g79Kueu4 July’s Molecules of the Month include Novartis' molecular glue degrader inducing fetal hemoglobin for sickle cell disease and Pfizer's tinlorafenib, a brain-penetrant BRAF V600E-mutant inhibitor targeting melanoma with brain metastasis. We also feature an MTA-cooperative PRMT5 inhibitor for MTAP-deficient cancers, a lysine-targeting kinase inhibitor, and a potentially attractive new target for Alzheimer’s disease. Read the full article to find out what compounds made our July 2024 Molecules of the Month list and check out recent articles for each. Full Article: https://lnkd.in/g79Kueu4

#OncUpdates In March 2024 FDA approved the use of Amivantamab (Rybrevant) in combination with carboplatin chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation, this rare type of NSCLC is usually resistant to the more traditional tyrosine kinase inhibitors therapy. Amivantamab is an antibody that targets both epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET), the phase 3 PAPILLON clinical trial showed that progression-free survival (PFS) in the study arm using a combination of Amivantamb-chemotherapy was 11.4 months, compared to 6.7 months in the chemotherapy only arm. The most notable adverse event, as mentioned by Tammy McClellan, PharmD in Cancer Network, was a higher rate of infusion-related reactions, the approach to this is splitting the initial dose between days 1 and 2 instead on giving it on one day. NEJM Article: https://lnkd.in/dzagRFKw

Around 35% of ovarian cancer patients are expected to be positive for folate receptor alpha (FRα)1, meaning over a third of people with advanced ovarian cancer may have a different treatment option. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy. Today’s #TestMenuSpotlight is on the FOLR1 FDA (ELAHERE™) for Ovarian Carcinoma. Visit us online to learn more: https://lnkd.in/gq7pJEhq 1: Matulonis UA, et al. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. J Clin Oncol. 2023 May 1;41(13):2436-2445. PMID: 36716407

First CAPItello was negative 😢 Published June 2024, relatively old 😊 The CAPItello-290 Phase III trial for capivasertib + paclitaxel in patients with locally advanced (inoperable) or metastatic TNBC did not meet the dual primary endpoints of improvement in (OS) versus paclitaxel + placebo in either the overall trial population or in a subgroup of patients with tumours harbouring specific biomarker alterations (PIK3CA, AKT1 or PTEN) 😔 Waiting the other CAPItello-292 which is now recruiting:💪🏽 Assesssing Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in ER+ and HER 2 - locally Advanced, Unresectable or Metastatic Breast Cancer BUT even comes with positive, still it was much important to have positive results in mTNBC which is the big unmet need. Also, some concerns about toxicity and impact of QOL of adding Capivasertib to CDK4/6 inhibitors But anyway, all of us are curious to see CAPItello 292 results 🤓

In advance of #ASCO, deepen your understanding of PD1/PD-L1 immune checkpoint inhibitors with our guide. Download our white paper for insights on the strengths, challenges, and potentials of inhibitors in diverse cancers. Stay tuned for more insightful #oncology resources from TFS as we approach ASCO. We invite you to stop by our booth #26149 to discuss your findings and insights with our authors and oncology experts. See you there! https://bit.ly/49e8ACe

Scancell Ltd Holdings PLC (AIM:SCLP, OTC:SCNLF) has rolled out its roadmap for the next 18 months, which builds on the significant clinical progress made to date. An early milestone comes from the release of full cohort data for SCIB1 and iSCIB1+ (for melanoma) in late 2024 and early 2025. The cancer immunotherapy specialist also plans to launch a phase II/III registration trial for SCIB1 or iSCIB1+ in 2025. In the first stage of the phase II study of SCIB1, 11 out of 13 patients achieved at least a partial response, exceeding the 70% overall response rate the trial was configured to show. Additionally, data from the ModiFY study in renal cell carcinoma (RCC), using Modi-1 in combination with checkpoint inhibitors, is expected in the first half of 2025. The company is also focused on exploring partnering or out-licensing opportunities for its GlyMab and AvidiMab platforms.  The update was provided alongside results for... More at #Proactive #ProactiveInvestors http://ow.ly/HivJ105JH51